Outcomes of the May 2021 PBAC intracycle meeting

18 June 2021 - The outcomes from the May 2021 PBAC meeting are now available. ...

Read more →

TLV receives a new assignment for precision medicine and advanced therapy drugs

15 June 2021 - The Swedish Dental and Pharmaceutical Benefits Agency, TLV, is commissioned by the government to continue the ...

Read more →

Health care funding decisions and real world benefits: reducing bias by matching untreated patients

14 June 2021 - Governments and health insurers often make funding decisions based on health gains from randomised controlled trials.  ...

Read more →

How the patient voice is becoming vital for drug approval

14 June 2021 - Rebecca Sanders from Lipodystrophy UK tells us how the patient voice helped convince NICE to approve a ...

Read more →

Opdivo plus Yervoy scores NICE backing for certain bowel cancer patients

14 June 2021 - Bristol Myers Squibb’s immunotherapy combination Opdivo plus Yervoy has been recommended by NICE for the treatment ...

Read more →

NICE to reassess Kyowa Kirin’s Poteligeo

14 June 2021 - NICE will reassess Kyowa Kirin’s rare blood cancer treatment Poteligeo after upholding an appeal launched by ...

Read more →

Astellas’ Xtandi bags NICE approval in prostate cancer

10 June 2021 - Astellas’ oral treatment Xtandi has received approval from NICE for the treatment of metastatic hormone-sensitive prostate ...

Read more →

NICE recommends several treatment options to help thousands with moderate rheumatoid arthritis

10 June 2021 - Around 25,000 people with moderate rheumatoid arthritis that has not responded to conventional therapies are set to ...

Read more →

Updated financial estimates workbook

10 June 2021 - An updated version of the Utilisation and Cost Model workbook and User Manual is now available to ...

Read more →

Integrating early economic evaluation into target product profile development for medical tests: advantages and potential applications

7 June 2021 - Target product profiles outline the characteristics that new health care technologies require to address an unmet clinical ...

Read more →

NICE recommends Tecentriq for first-line NSCLC

7 June 2021 - NICE has recommended Roche’s Tecentriq (atezolizumab) monotherapy for untreated metastatic non-small cell lung cancer. ...

Read more →

SMC - June 2021 decisions

7 June 2021 - Advice on five new medicines for use in conditions including advanced gastric cancer and chronic lymphocytic leukaemia ...

Read more →

ICER issues statement on the FDA’s approval of aducanumab for Alzheimer’s disease

7 June 2021 - The ICER believes that the FDA, in approving aducanumab (Aduhelm, Biogen) for the treatment of Alzheimer’s ...

Read more →

NICE publishes appraisal consultation document for medicine for excessive daytime sleepiness

3 June 2021 - The Department of Health and Social Care has asked the NICE to produce guidance on using pitolisant ...

Read more →

NICE turns down GSK's IV Benlysta for systemic lupus

4 June 2021 - NICE has rejected NHS funding for an intravenous formulation of GlaxoSmithKline's Benlysta (belimumab) as an add-on ...

Read more →